Breaking: Julia Vitarello Announces New Venture After Previous Company Folds
ROME — Julia Vitarello, whose daughter Mila received a one-of-a-kind gene therapy for a rare mutation eight years ago, is launching a new biotechnology company to mass-produce personalized medicines. Vitarello confirmed the effort exclusively to STAT, saying she is actively seeking investors for the still-unnamed startup.
“We learned how to make one drug for one child. Now we need to build a factory that can do it for hundreds of children,” Vitarello said in an interview Tuesday.
Previous Company Collapsed Over FDA Guidance Gap
Vitarello’s earlier venture, EveryONE Medicines, recently shuttered. She blamed insufficient FDA guidance on customized therapies for failing to create a viable investor pathway.
“The FDA took a step forward, but not far enough to de-risk the business model,” she explained.
FDA Encouragement Not Enough
The agency’s 2023 draft guidance encouraged development of individualized antisense oligonucleotides for ultra-rare diseases. However, Vitarello argued it lacked clear reimbursement and regulatory approval mechanisms.
“Investors saw too much uncertainty,” said Dr. Luca Raffaele, a gene therapy researcher at the University of Rome who is not involved with the new company. “Without a predictable path to profit, even the most noble science struggles to attract capital.”
Background: Mila’s Story and the Bespoke Medicine
Mila Vitarello was diagnosed with Batten disease, a fatal neurodegenerative disorder caused by a unique mutation. In 2017, researchers at Boston Children’s Hospital designed a custom antisense oligonucleotide—dubbed “milasen”—that dramatically slowed her decline.
Her case became a landmark for N-of-1 therapies, but scaling such treatments has proven difficult. Only a handful of similar drugs have been approved since.
The N-of-1 Challenge
Each bespoke drug targets a single patient’s genetic typo, making traditional clinical trials impractical. Manufacturing is costly and time-consuming, typically taking months.
Vitarello’s new company aims to develop platform technologies that shorten production timelines and reduce costs, potentially making these therapies accessible to thousands of patients with rare mutations.
What This Means for Patients and the Industry
If successful, the startup could unlock treatments for the estimated 400 million people worldwide with rare genetic diseases. Currently, the FDA has approved fewer than a dozen individualized therapies.
“Every child deserves a chance, not just those with common conditions,” Vitarello said. “We are building the manufacturing and regulatory infrastructure to make that possible.”
Key Hurdles Remain
- Funding: Vitarello declined to disclose target financing but said the new company will require “substantial” venture capital.
- Regulation: The FDA has not yet finalized its guidance on individualized therapies, leaving ambiguities around data requirements.
- Manufacturing: Scaling from one molecule per patient to dozens simultaneously demands parallel production lines and quality control systems.
Expert Reaction
Dr. Emma Laughlin, a bioethicist at Johns Hopkins, called the effort “bold but fraught.” She noted that “the moral imperative to treat every child clashes with the economic reality of high per‑patient costs.”
“Vitarello is facing three connected challenges: science, business, and regulation,” Laughlin added. “Her previous company couldn’t solve them all. The question is whether this new team can.”
Looking Ahead
Vitarello said she expects to announce the new company’s name and initial partners within three months. Meanwhile, Mila continues to thrive beyond all medical predictions.
“Mila is my inspiration, but she can’t be the only one,” Vitarello said. “The science exists to help many more children. Now we need the will—and the dollars—to make it happen.”